NCT06607458Phase 2Recruiting

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

Study sponsor: Delcath Systems Inc. · DCTH

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants90Estimated

Source updated2026-06-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Refractory Metastatic Colorectal Cancer

Treatments or interventions studied

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus BevacizumabDrugAlso known as Melphalan, HDS, Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil, Melphalan/HDS
Trifluridine-tipiracil plus Bevacizumab AloneDrugAlso known as Trifluridine-tipiracil, Bevacizumab

Primary outcomes · main study measures

measure: hPFS; description: Hepatic Progression Free Survival; timeFrame: time from randomization to the first occurrence of hepatic disease progression, assessed over 24 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history